Please see full Prescribing Information for ZORYVE. ZORYVE is for topical use only and not for ophthalmic, oral, or intervaginal use. Arcutis cautions you that statements contained in this press ...

General Medicines Growth: 7% for the quarter. Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix. Core Operating Profit Growth: 5% excluding COVID. Core EPS Growth: ...

Big pharma has long been a force for commercial broadcasters. Promotions for GSK’s respiratory vaccine Arexvy and its blockbuster shingles shot Shingrix are a big presence. But despite all the ...

“We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted Arexvy, indicating our potential best-in-class ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the US public health agency narrowed the age recommendation for use of RSV vaccines and ...

The U.K. firm, whose vaccines include Arexvy and Shingrix, now expects 2024 vaccine sales to decrease by a low-single digit percentage. GSK's (GSK) shares are falling 4% in premarket trading ...

The content of this article is provided for information purposes only and is ... So the pipeline is strengthening. The Arexvy development is disappointing for GSK shareholders, as it seemed ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling ...

Vaccine sales performance was primarily impacted by lower sales of Arexvy with changes in Advisory Committee on Immunization Practices (ACIP) guidelines, prioritization of COVID-19 vaccinations in ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

GSK shares fell on Wednesday after the group's vaccine sales continued to disappoint in the third quarter. The drugmaker saw weaker-than-expected demand for its respiratory syncytial virus (RSV ...